Printer Friendly

DR. LIONEL RESNICK CONFIRMS IMPORTANT DEVELOPMENT IN AIDS TREATMENT

 BOYNTON BEACH, Fla., Oct. 13 /PRNewswire/ -- Polydex Pharmaceuticals Limited (NASDAQ: POLXF), announced today that Dr. Lionel Resnick, a consultant to the NIH (National Institute of Health) and Dr. Mariano Busso, both of Mount Sinai Medical Center, Miami, Fla., have confirmed an important development in AIDS treatment.
 Dr. Resnick, chief virologist at Mount Sinai Hospital, has tested AZT for the NIH and reported today that results of tests performed in his laboratories on a new drug consisting of a conjugate of Dextran and AZT is effective against the AIDS virus in vitro.
 Dr. Resnick further stated that he believes that this conjugate will substantially reduce both the toxicity and the cost of AZT when given to humans.
 Polydex Pharmaceuticals developed this conjugate and has a patent pending. Under an agreement with Burroughs Wellcome (the patent holder of AZT), Polydex has provided data and samples of the conjugate to Burroughs Wellcome for testing.
 Polydex founded in 1972, is one of the world's leaders in the production of dextran-based products.
 -0- 10/13/93
 /CONTACT: Ron Como & Associates, Inc, 212-227-3010/
 (POLXF)


CO: Polydex Pharmaceuticals Limited ST: Florida IN: HEA SU:

WB-SH -- NY039 -- 1602 10/13/93 11:05 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 13, 1993
Words:196
Previous Article:AAR SELLS $50 MILLION OF 7-1/4 PERCENT NOTES DUE 2003
Next Article:THE LEATHER FACTORY, INC. ANNOUNCES SIGNING OF LETTER OF INTENT
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters